Other

Amgen 4Q profit drops 16 pct. on higher spending

Drugmaker Amgen Inc. on Wednesday posted a 16 percent drop in fourth-quarter profit, as higher costs for production, marketing, research and other items offset higher sales for many of its biologic medicines. The results ...

Diseases, Conditions, Syndromes

New marker for better assessing the severity of COVID-19

Biomedical scientists at LMU have found a new marker in the blood of COVID-19 patients. It furnishes insights into the course and development of the disease and could lead to better diagnoses.

Diseases, Conditions, Syndromes

WHO scraps plan for interim report on Wuhan virus mission: WSJ

The World Health Organization has scrapped plans for a team that visited Wuhan, China to probe the origins of the coronavirus pandemic to issue an interim report, The Wall Street Journal reported late Thursday.

Cardiology

The Janus-like nature of JAM-A

A new study by Ludwig-Maximilians-Universitaet (LMU) in Munich researchers led by Christian Weber sheds light on the role of the adhesion molecule JAM-A in the recruitment of immune cells to the inner layer of arteries – ...

Other

Amgen tops Street 4Q forecasts

Amgen Inc. cruised to a 27 percent jump in fourth-quarter profit and beat Wall Street expectations, due to higher sales of nearly all its medicines, tight cost controls and a tax benefit.

Other

New meds help drugmakers weather strong dollar, other issues

Revenue from important new medicines for various cancers, hepatitis C and more helped top U.S. drugmakers weather unfavorable currency exchange rates and other challenges. Pfizer Inc., Merck & Co. and Bristol-Myers Squibb ...

page 40 from 40